Avalon GloboCare Corp.
Avalon GloboCare Corp. (Nasdaq: ALBT) is a clinical-stage biotechnology company dedicated to develop and deliver innovative and transformative CellTech with multifunctional convergence in cellular technologies/therapeutics, precision diagnostics and intellectual property in the field of immuno-oncology and cellular medicines.
Nasdaq: ALBT
IR Website: https://ir.avalon-globocare.com/
Headquarters: Freehold, NJ
The company’s core technology platforms include cellular therapies (CAR-T, CAR-NK, mRNA-based Flash-CARTM), Avalon clinical-grade tissue-specific exosomes (ACTEXTM), and precision companion diagnostics related to cellular medicines.
TALK TO MANAGEMENT
The Avalon Globocare management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Avalon GloboCare (Nasdaq: ALBT) is a clinical-stage biotech company focused on immuno-oncology and cellular medicines. Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and precision companion diagnostics.
Founded in 2016 as an OTCQB company, Avalon GloboCare successfully uplisted to NASDAQ in December 2018. It currently has partnerships with two major universities that focus on CAR-T refinement, applications and bio-production, and a biotech skin care company to advance product commercialization with Avalon’s regenerative ACTEX™ platform. Underpinning Avalon’s R&D pipeline is a broad and deep intellectual property portfolio, covering a number of key enabling technologies and addressing multi-billion dollars of unmet CellTech market worldwide.
• Purchased headquarters building in Freehold/New Jersey in 2017 (USD $8M), which generates average annual revenue of USD $1.2M
• Successfully filed for USD $50M mixed shelf offering (S3) in January 2019
• Chairman provided USD $20M credit facility, enabling acceleration of R&D and clinical programs
• Shares outstanding: 82M
Press Releases
Investor Presentation
To download the Avalon GloboCare investor presentation, please fill out the form below.
Stock Chart (Intraday)
Stock Chart (Historical)
Stock Detail
Video: Bezinga Presents an Interview with Avalon GloboCare
CAR-T Cells and Their Transformational Promise
CAR-T therapy is a treatment in which a patient's T-cells (a common type of immune cells) are manipulated in a laboratory in order to make them efficiently destroy cancer cells. A gene for a special receptor, called a Chimeric Antigen Receptor (CAR), is binded to a certain protein on the cancer cells and is integrated into the T-cells in the laboratory. Large amounts of those CAR-T cells are then infused into the patient by injection. While it is currently used to treat blood cancers with strong efficacy, the potential possibilities are endless, and this is where Avalon GloboCare is looking to make their impact.
One of the current limitations of CAR-T therapies is their induction of "cytokine storms", which are immune responses that are often disruptive to tissue and lead to inflammation, amongst other issues. Avalon's AVA-1904B treatment has shown significantly lower cytokine storm issues; it entered Phase 1 clinical trials in Q3 2021, and may lead to incredible advancements going forward.
While Avalon GloboCare didn't invent CAR-T therapies, they are making breakthroughs that may turn it from a niche treatment specializing in one particular field (blood cancers) and give it practical applications to many more fields, thus expanding its potential use exponentially.
CAR-T Market Size
Cancer Impacts Us All, but CAR-T Therapies Can Change That
The incredible burden that not just blood-born cancers, but cancer in general has created to families, individuals, and the health care system can't be ignored. This has led to a notable surge in interest in CAR-T therapies and their potential case uses past blood cancers, which Avalon GloboCare (Nasdaq: ALBT) has surged into a leadership position for.
CAR-T cell therapy is estimated to become a $21.8 billion industry within the next decade, according to Bloomberg. From 2020 to 2028, it is estimated to grow at a 35% Compounded Annual Growth Rate (CAGR), compared to a 13.6% CAGR for the S&P 500 last decade. Numerous megadeals in the CAR-T space have occurred over the last few years, including Gilead's purchase of Kite for $11.9B, Celgene's purchase of Juno for $9B, and then BMS's takeover of Celgene for $74B.
The interest and growth in the area has already been intense, and as the science continues to be refined, that will likely only further.
Exosomes - What Are They and How is ALBT Using Them?
What Are Exosomes, and How is Avalon GloboCare Using Them?
Exosomes are essentially tiny pockets of biomolecules which are essentially excreted from nearly every type of cell. Once thought to be a kind of disposal system for cells, exosomes are now known to be far more important than that. Exosomes have been shown to play a part in cell to cell transit, delivering numerous types of lipids, proteins and nucleic acids from cell to cell
The exosomes released by regenerative cells such as stem cells, for example, are significant drivers of cellular repair, and exosomes from diseased cells could play a major role in diagnosing cancers at an early stage.
Leveraging the company’s scientific and clinical expertise in cellular therapy and stem cell-derived exosome (ACTEX) technology, Avalon GloboCare is currently in testing for use of its ACTEX technology for numerous applications ranging from skincare to weight management to neurodegenerative disorders.
Avalon GloboCare has partnered with HydroPeptide, a restorative skin-care company, in order to to accelerate ALBT's regenerative ACTEX™ product development and commercialization, thus demonstrating the potential flexibility of their biotech capabilities.
Regenerative Therapy Market
According to the NIH, regenerative therapy is defined as the therapeutic application of stem cells and/or progenitor cells based on their potential to stimulate repair mechanisms and restore function in damaged body tissues or organs. Potential applications are in anti-aging medicines, disease treatment, trauma recovery, and tissue engineering.
According to Verified Market Research, the global regenerative therapy market was valued at $27.7 billion in 2020 but was predicted to grow to $149.8 billion in 2028, penciling out to an impressive compound annual growth rate of 23.5%.
Avalon GloboCare has partnered with HydroPeptide, a restorative skin-care company, in order to to accelerate ALBT's regenerative ACTEX™ product development and commercialization, demonstrating the potential of entering an entire new vertical with their biotech capabilities.
Current Candidates
ALBT plans to expand its CAR-T assets to include 15 cell therapy candidates (autologous and universal), targeting both hematologic malignancies and solid tumors, as well as a 16,000 sq ft in-house GMP facility with large scale bio manufacturing and process development capacities.
Strategic Partnerships
Bringing a successful drug from an idea to a commercial success is best achieved by bringing value throughout the entire process.
Avalon’s upstream partnerships and innovative research includes:
-
Co-development of Avalon Clinical-grade Tissue-specific Exosome (ACTEXTM) with Weill Cornell Medicine.
-
Novel therapeutic and diagnostic targets development utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT). They have combined forced with Google’s DeepMind artificial intelligence (AI) program, AlphaFold2, to accurately predict the 3D structures of protein receptors that have potential use as cellular therapy targets.
-
Co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK and other immune effector cell therapeutic modalities with Arbele Corp.
Additionally, Avalon GloboCare has partnered with HydroPeptide, a restorative skin-care company, in order to to accelerate ALBT's regenerative ACTEX™ product development and commercialization, demonstrating the potential of entering an entire new vertical with their biotech capabilities.
Financials
Loren Ipsum
SEC Filings
Board of Directors and Advisory Board
Senior Management Bios
David Jin, M.D., Ph.D.
Chief Executive Officer, President
David Jin, MD, Ph.D., a director and Chief Executive Officer of the Company and AHS.
From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology.
Dr. Jin previously served as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University.
Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters.
Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology.
Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015 and 2018.
Luisa Ingargiola
Chief Financial Officer
Luisa Ingargiola has almost 20 years of experience in public company finance, compliance and capital markets oversight. She currently serves as Audit Chair for several companies including Dragonfly Energy (DFLI) and Audit Chair of Electra Mecchanica (ECCTF). She has held various positions as Chief Financial Officer or Audit Chair with several public companies and has helped manage over $100 Million in financing.
Ms. Ingargiola has helped guide the uplist of several OTC companies to NASDAQ or the NYSE. She graduated from Boston University with a Bachelor Degree in Business Administration and received her MBA in Health Administration from the University of South Florida.
Meng Li
Chief Operating Officer
Meng Li is Chief Operating Officer, Secretary and a member of the Board of Directors.
Ms. Li has over 15 years of executive experience in international marketing, branding, communication, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenithmedia (a Publicis Group company) from 2000-2006 as Senior Manager.
Ms. Li received a Bachelor of Arts in International Economic Law from University of Dalian Maritime University, China.
Daniel Lu
Chairman of the Board
Daniel Lu is Chairman of the Board of the Company and AHS.
Mr. Lu is a seasoned healthcare entrepreneur with extensive operation in China. He has been serving as Chairman of the Board for the DaoPei Medical Group (“DPMG”) since 2010. Under his leadership, DPMG has recently expanded its clinical network involving a state-of-the-art stem cell bank at Wuhan Biolake, three top-ranked private hospitals (located in Beijing, Shanghai, and Hebei), specialty hematology laboratories, as well as a hematology research institute, with more than 100 partnering and collaborating hospitals in China. DPMG was founded by Professor Daopei Lu, a renowned hematologist pioneering in hematopoietic stem cell transplant and member of the Academy of Engineering in China.
Mr. Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently worked as senior Art Director at Ogilvy & Mather Advertising Company. Prior to joining DPMG, Mr. Lu served as Chief Operating Officer for BioTime Asia Limited which is a subsidiary of BioTime, Inc. (NYSE/AMEX:BTX) in 2009.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Avalon GloboCare, Corp. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i Digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
b2i Digital or its related entities may own securities of the Company.
To comply with Rule 17(b) of the Securities Act of 1933, as amended, b2i Digital must provide full disclosure of all compensation received for investor awareness services provided by the Company.
The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.
The Avalon GloboCare Corp. management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
• Directly hear the Avalon GloboCare Corp. story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible
Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.
